Citation Impact
Citing Papers
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
2017
Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer
2021 StandoutNobel
EglN2 associates with the NRF 1‐ PGC 1α complex and controls mitochondrial function in breast cancer
2015 StandoutNobel
Colorectal cancer statistics, 2023
2023 Standout
Breast cancer
2019 Standout
Breast-cancer detection using blood-based infrared molecular fingerprints
2021 StandoutNobel
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
A view on drug resistance in cancer
2019 StandoutNature
Physical Principles of Membrane Shape Regulation by the Glycocalyx
2019 StandoutNobel
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
2017
Pancreatic cancer
2020 Standout
Integrating liquid biopsies into the management of cancer
2017
Liquid Biopsies, What We Do Not Know (Yet)
2017
The immune contexture in cancer prognosis and treatment
2017 Standout
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
2020
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Colorectal cancer
2019 Standout
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
2016
Personalised medicine and population health: breast and ovarian cancer
2018
Tunneling Nanotubes
2012
Liquid biopsy
2015
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
2015
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
2017 Standout
Cellular Fatty Acid Metabolism and Cancer
2013 Standout
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
Biomarker-driven and molecular targeted therapies for colorectal cancers
2017
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
2019
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
2015
Colorectal cancer statistics, 2017
2017 Standout
Artificial intelligence in cancer imaging: Clinical challenges and applications
2019 Standout
Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer
2016
Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning
2012
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
2020
Works of Bryan K. Kee being referenced
Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer
2012
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer
2017
Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer
2014
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
2015
Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature
2013
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study
2017
Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer.
2014
HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.
2016
Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin
2016
Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers.
2015
Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer.
2014